This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments

Like
Comment
Favorite

This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments

Motley Fool09-18 22:07

Terns Pharmaceuticals recently posted positive results from a clinical trial involving a weight-loss pill. The results looked better than those from a key rival. The company recently ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2468058216?lang=en_US&edition=fundamental","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F790696%2Fa-person-trying-to-lose-weight-and-who-is-measuring-their-waist.jpg&op=resize&w=165&h=104","is_english":true,"pubTime":"2024-09-18 22:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2468058216","market":"us","top_or_hot":-1,"title":"This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments","media":"Motley Fool","content":"<div>\n<p>Terns Pharmaceuticals recently posted positive results from a clinical trial involving a weight-loss pill.\n\n\n\n\n\n\n\nThe results looked better than those from a key rival.\n\n\n\n\n\n\n\nThe company recently ...</p>\n\n<a href=\"https://www.fool.com/investing/2024/09/18/this-small-cap-stock-has-a-promising-glp-1-drug-wh/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-18 22:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2024/09/18/this-small-cap-stock-has-a-promising-glp-1-drug-wh/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Terns Pharmaceuticals recently posted positive results from a clinical trial involving a weight-loss pill.\n\n\n\n\n\n\n\nThe results looked better than those from a key rival.\n\n\n\n\n\n\n\nThe company recently ...</p>\n\n<a href=\"https://www.fool.com/investing/2024/09/18/this-small-cap-stock-has-a-promising-glp-1-drug-wh/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4590","symbol_name":"PTP","start_time":0,"source_url":"https://www.fool.com/investing/2024/09/18/this-small-cap-stock-has-a-promising-glp-1-drug-wh/","article_id":"2468058216","we_media_id":null,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F790696%2Fa-person-trying-to-lose-weight-and-who-is-measuring-their-waist.jpg&op=resize&w=165&h=104"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2468058216","pubTimestamp":1726668420,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"Terns has a modest market cap of less than $800 million, and its possible upside could be massive.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4590":"PTP","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU0238689110.USD":"贝莱德环球动力股票基金","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","BK4144":"石油与天然气的储存和运输","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LLY":"礼来","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4585":"ETF&股票定投概念","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","NVO":"诺和诺德","LU0058720904.USD":"联博国际健康护理基金A","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","GLP":"全球合伙","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","BK4588":"碎股","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU0122379950.USD":"贝莱德世界健康科学A2","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","BK4581":"高盛持仓","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC"},"translate_title":"这只小盘股有一种很有前途的GLP-1药物，可以与诺和诺德和礼来的减肥治疗相媲美","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1,"GLP":1,"LLY":0.8},"content_text":"Terns Pharmaceuticals recently posted positive results from a clinical trial involving a weight-loss pill.\n\n\n\n\n\n\n\nThe results looked better than those from a key rival.\n\n\n\n\n\n\n\nThe company recently announced a stock offering, and more could be coming as this is still a cash-burning business.\n\nGoldman Sachs projects that the anti-obesity market will be worth as much as $100 billion by the end of the decade. It's currently dominated by a few big names in Eli Lilly and Novo Nordisk, but that can change drastically in the future. The best-selling glucagon-like peptide-1 (GLP-1) weight-loss treatments today are injections, but companies are working on pills which could be more attractive to patients, especially if they need to take them on a long-term basis.One stock that investors will want to keep a close eye on is Terns Pharmaceuticals (TERN 7.79%). Its shares recently jumped on some positive clinical-trial results, and it could have a possible drug which fights for market share in the fast-growing, anti-obesity market.Early-trial results show reason for optimismOn Sept. 9, California-based Terns Pharmaceuticals reported that its once-daily GLP-1 pill, TERN-601, was well tolerated in a recent clinical trial which lasted 28 days. The placebo-adjusted mean weight loss among participants was 4.9% when taking the highest dosage (740mg). And more than two-thirds of people involved in the trial lost over 5% of their body weight. The results are promising when considering that rival Viking Therapeutics' (VKTX 1.21%) oral drug VK2735 achieved a placebo-adjusted weight loss of up to 3.3% over a 28-day period in a recent trial. It is notable, however, that the highest dosage in that trial was much smaller at 40mg. Investors, however, will still likely be bullish on those types of comparisons as Viking Theraputics has a market cap of $7.4 billion, which is around 10 times what Terns is worth today.In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve more than 13% weight loss, but that has been over much longer time frames, ranging between 36 to 68 weeks.  Terns says that it will move forward with phase 2 trials of its weight-loss drug next year.Investors should brace for volatility with Terns stockShares of Terns have been rallying on the recent results, and the healthcare stock is now up around 40% this year. But in recent days, the stock has given back some gains after announcing a $150 million offering. It isn't unusual for a stock to use a rally to help raise cash afterwards, since a higher stock price will mean issuing fewer shares (or, have a lower stock dilution) to raise the required capital.As Terns spends more money on developing its weight-loss pill, investors should expect that there will be more offerings ahead to help with its cash-flow needs. In the trailing 12 months, the company has burned through just under $79 million from its day-to-day operating activities.Losses and cash burn are going to continue for the foreseeable future as Terns does not have an approved product in its portfolio. Even if future clinical trials are encouraging, the need for ongoing stock offerings makes it probable that it will be a bumpy path forward for investors who own shares of Terns.Should you invest in Terns Pharmaceuticals today?The early trial of TERN-601 is encouraging, but I wouldn't buy shares of the stock just yet. It's still far too early in the process to be confident that the weight-loss pill will come to market. There's always going to be a risk when it comes to biotech stocks, but the key is to minimize it. Right now, while Terns' valuation is low, investors need to remember that the field is getting crowded in the anti-obesity market, and competition could be fierce in the future. By the time that Terns' drug comes to market (assuming that it is successful), there may be other, more effective weight-loss treatments which emerge.This is a high-risk, high-reward type of investment. If you can afford to make a modestly sized investment in the stock, knowing that you can incur significant losses if TERN-601 fails and are comfortable with that risk, then this may be an investment worth considering given how significant the upside could be for Terns. But for most investors, I'd suggest taking a wait-and-see approach with the stock, as there's still a lot of risk and uncertainty involved with this investment.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}